LITTLETON, MASS., August 4, 2015 – Mevion Medical Systems, the leading provider of advanced proton therapy systems, announced today that it has entered into an investment agreement where up to $200 million will be invested in Mevion to accelerate its worldwide expansion. The investment was led by HOPU Investments, YuanMing Capital, and participated in by other Chinese investors and existing U.S. investors Caxton Alternative Management L.P., ProQuest Investments, Venrock and CHL Medical Partners. Concurrent with the investment, Mevion and the lead investors will form a joint venture in China to produce, sell and service proton therapy systems for the Chinese market. HOPU and YuanMing have extensive experience investing in successful healthcare companies and offer a significant network of healthcare experience in China.

With a cadre of international investors supporting its proton therapy leadership position, Mevion is poised to significantly expand its business globally and dramatically increase access to this important cancer therapy around the world. The investment will support an increase in Mevion’s manufacturing capacity and global service capability to support the installation of new proton therapy sites in the U.S., China and internationally.

“This investment is a clear endorsement of Mevion’s unique leading-edge proton therapy technology. No other system can match the quality, size, cost, and efficiency of the MEVION S250, making it a powerful and practical solution for proton centers globally,” said Joseph K. Jachinowski, President and CEO of Mevion Medical Systems. “Mevion has more modular proton therapy systems ordered, installed and treating than all other manufacturers combined. And, the compelling clinical and business results from our operational systems, and the momentum we are building, is powerful evidence that the future is bright, both for Mevion and for the cancer patients who will benefit from having wider access to proton therapy.”


“Proton therapy is an increasingly significant treatment modality for cancer centers around the world, and we see real value in advancing accessibility to this important therapy in China and elsewhere,” said Sunny Li, Senior Managing Director and Head of Technology Investments of HOPU Investments. “We have conducted an extensive industry survey of proton therapy companies, Only one company is commercially proven to have both the best technology and the best economics for healthcare providers and that is Mevion. We wanted to be a part of this success story.”

More HCB News